Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016', provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- The report reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics and enlists all their major and minor projects
- The report assesses Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview 6
Therapeutics Development 7
Pipeline Products for Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview 7
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics under Development by Companies 8
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Products under Development by Companies 11
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development 12
Coherus BioSciences, Inc. 12
Epirus Biopharmaceuticals, Inc. 13
Marathon Pharmaceuticals, LLC 14
Mycenax Biotech Inc. 15
Oncobiologics, Inc. 16
Oncodesign SA 17
Panacea Biotec Limited 18
Sandoz International GmbH 19
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
adalimumab biosimilar - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
adalimumab biosimilar - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
deflazacort - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
etanercept biosimilar - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
etanercept biosimilar - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
etanercept biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
etanercept biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
methotrexate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
tocilizumab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tocilizumab biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
tocilizumab biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Recent Pipeline Updates 42
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences, Inc., H1 2016 12
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 13
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 14
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc., H1 2016 15
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics, Inc., H1 2016 16
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2016 17
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Limited, H1 2016 18
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Polyarticular Juvenile Idiopathic Arthritis (PJIA) Therapeutics - Recent Pipeline Updates, H1 2016 42
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2016 46